Ingredion (INGR) CEO Exercises Options; 36,287 Shares Sold at ~$126.52
Rhea-AI Filing Summary
James P. Zallie, President and CEO and a director of Ingredion Inc. (INGR), reported transactions on 08/12/2025 showing the exercise of employee stock options and a contemporaneous sale of common stock. The filing discloses option exercises of 96,316 and 128,522 shares with exercise prices of $91.85 and $88.35, respectively, and a sale of 36,287 shares at a weighted average price of $126.523 (prices ranged $126.50–$126.60).
The Form 4 notes that 11,677.519 and 17,183.160 shares were withheld to pay applicable taxes from two reported transactions, with the remainder of withheld share amounts used to cover exercise prices (81,634 and 106,917 reported in those line items). The statement was signed by attorney-in-fact Michael N. Levy on 08/14/2025.
Positive
- None.
Negative
- None.
Insights
TL;DR: CEO Zallie exercised options totaling 224,838 shares and sold 36,287 shares at ~$126.52; withholding covered taxes and exercise costs.
The Form 4 documents option exercises of 96,316 and 128,522 shares, implying 224,838 shares were issued on exercise. The filing shows a sale of 36,287 shares at a weighted average price of $126.523, with reported tax withholdings of 11,677.519 and 17,183.160 shares against two transactions. Exercise prices are disclosed at $91.85 and $88.35, which indicates intrinsic gains on the exercised options at the reported sale price levels. All observations are limited to the facts reported on the Form 4.
TL;DR: Routine insider reporting: option exercises and partial sale with tax withholding, certified by attorney-in-fact.
The report identifies James P. Zallie as both President and CEO and a director, and shows compliance with Section 16 reporting via a Form 4 filed by one reporting person. The filing documents option exercises, share withholding to cover taxes and exercise prices, and a multi-price sale (range $126.50–$126.60). The signature block shows the form was signed by an attorney-in-fact, Michael N. Levy, on 08/14/2025. The filing contains no additional governance actions or amendments beyond the transactions disclosed.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Options (Right to Buy) | 96,316 | $0.00 | -- |
| Exercise | Employee Stock Options (Right to Buy) | 128,522 | $0.00 | -- |
| Exercise | Common Stock | 96,316 | $91.85 | $8.85M |
| Tax Withholding | Common Stock | 81,634 | $126.46 | $10.32M |
| Exercise | Common Stock | 128,522 | $88.35 | $11.35M |
| Tax Withholding | Common Stock | 106,917 | $126.54 | $13.53M |
| Sale | Common Stock | 36,287 | $126.523 | $4.59M |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Of this amount, 11,677.519 shares were withheld to pay applicable taxes and the remainder was withheld to pay the exercise price for the stock options. Of this amount, 17,183.160 shares were withheld to pay applicable taxes and the remainder was withheld to pay the exercise price for the stock options. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.50 to $126.60, inclusive. The reporting person undertakes to provide full information as requested regarding the number of shares sold at each separate price. Includes restricted stock units ("RSUs") acquired through deemed dividend reinvestment. RSUs acquired through deemed dividend reinvestment vest on the dates when the RSUs with respect to which they are deemed dividends vest. These options vested in three equal annual installments on February 8, 2020, 2021 and 2022. These options vested in three equal annual installments on February 4, 2021, 2022 and 2023.
